After first cancer vaccine success, race widens to more tumor types

· Health · Spain

At ESMO in Madrid, Merck and Moderna's personalized cancer vaccine data drew a packed presidential symposium, with one observer calling it "a triumph of science." The presentation follows the first effective cancer vaccine after roughly a century of effort, and attention is now turning to whether the approach can be extended beyond melanoma to other tumor types. Endpoints reported that the work now begins on broadening the vaccine's impact, while STAT described a race among developers to make personalized cancer vaccines work in more cancers.

Why it matters：A validated personalized cancer vaccine platform would open a new treatment modality and a manufacturing and biomarker race across oncology.

Key points

  • The presidential symposium hall was full for the Merck-Moderna data.
  • The vaccine is described as the first effective cancer vaccine after about 100 years of effort.
  • Developers are now pushing to extend it to more tumor types.

Sources (original reporting)

More stories from this day